Guselkumab (Tremfya, Janssen-Cilag) is indicated 'for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor'.
The dosage schedule is available in the summary of product characteristics for guselkumab.
The list price of guselkumab is (excluding VAT; company submission):
£4,500 for a 200-mg solution for infusion vial
£2,250 for a 100-mg pre-filled pen
£2,250 for a 200-mg pre-filled pen.
The company has a commercial arrangement. This makes guselkumab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, Janssen-Cilag did not disclose its Carbon Reduction Plan for UK carbon emissions.